NOTICE OF CALL OF THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING The shareholders of Genenta Science S.p.A. are invited to attend the next ordinary and extraordinary. | May 10, 2023
Effectiveness of the Amended and Restated OSR License Agreement As previously disclosed in the Annual Report on Form 20-F for the fiscal year ended December 31, 2022 of Genenta. | May 1, 2023
MILAN, Italy and NEW YORK, April 03, 2023 Genenta Science , a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide. | April 3, 2023